Click Here for 5% Off Your First Aladdin Purchase!

Edicotinib - 98%, high purity , Macrophage colony stimulating factor receptor inhibitor, CAS No.1142363-52-7, Macrophage colony stimulating factor receptor inhibitor

  • Moligand™
  • ≥98%
Item Number
E610067
Grouped product items
SKUSizeAvailabilityPrice Qty
E610067-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,334.90
E610067-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$199.90
E610067-25mg
25mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$2,001.90
E610067-50mg
50mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$559.90
E610067-100mg
100mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$779.90

Basic Description

SynonymsEdicotinib|1142363-52-7|JNJ-40346527|Edicotinib [USAN]|JNJ40346527|3NU609VYNF|EdicotinibJNJ-40346527|Edicotinib (USAN)|4-Cyano-1H-imidazole-2-carboxylic acid N-(2-(4,4-dimethylcyclohex-1-enyl)-6-(2,2,6,6-tetramethyltetrahydropyran-4-yl)pyridin-3-yl)amide|
Specifications & Purity98%
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeINHIBITOR
Mechanism of actionMacrophage colony stimulating factor receptor inhibitor
Product Description

Edicotinib (JNJ-40346527) is a potent, selective, brain penetrant and orally active colony-stimulating factor-1 receptor (CSF-1R) inhibitor with an IC50 of 3.2 nM. Edicotinib exhibits less inhibitory effects on KIT and FLT3 with IC50 values of 20 nM and 190 nM, respectively. Edicotinib limits microglial expansion and attenuates microglial proliferation and neurodegeneration in mice. Edicotinib has the potential for Alzheimer’s disease and rheumatoid arthritis research.

Product Properties

ALogP4.3

Associated Targets

CSF1R Tclin Macrophage colony-stimulating factor 1 receptor 3 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

FLT3 Tclin Receptor-type tyrosine-protein kinase FLT3 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

KIT Tclin Mast/stem cell growth factor receptor Kit 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

IUPAC Name 5-cyano-N-[2-(4,4-dimethylcyclohexen-1-yl)-6-(2,2,6,6-tetramethyloxan-4-yl)pyridin-3-yl]-1H-imidazole-2-carboxamide
INCHI InChI=1S/C27H35N5O2/c1-25(2)11-9-17(10-12-25)22-21(32-24(33)23-29-16-19(15-28)30-23)8-7-20(31-22)18-13-26(3,4)34-27(5,6)14-18/h7-9,16,18H,10-14H2,1-6H3,(H,29,30)(H,32,33)
InChi Key BNVPFDRNGHMRJS-UHFFFAOYSA-N
Canonical SMILES CC1(CCC(=CC1)C2=C(C=CC(=N2)C3CC(OC(C3)(C)C)(C)C)NC(=O)C4=NC=C(N4)C#N)C
Isomeric SMILES CC1(CCC(=CC1)C2=C(C=CC(=N2)C3CC(OC(C3)(C)C)(C)C)NC(=O)C4=NC=C(N4)C#N)C
Alternate CAS 1142363-52-7
PubChem CID 25230468
MeSH Entry Terms 4-cyano-N-(2-(4,4-dimethylcyclohex-1-en-1-yl)-6-(2,2,6,6-tetramethyl-tetrahydro-2H-pyran-4-yl)pyridin-3-yl)-1H-imidazole-2-carboxamide;JNJ-40346527
Molecular Weight 461.60

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

10 results found

Lot NumberCertificate TypeDateItem
G2411176Certificate of AnalysisMar 27, 2024 E610067
G2411177Certificate of AnalysisMar 27, 2024 E610067
G2411178Certificate of AnalysisMar 27, 2024 E610067
G2411179Certificate of AnalysisMar 27, 2024 E610067
G2411185Certificate of AnalysisMar 27, 2024 E610067
G2411186Certificate of AnalysisMar 27, 2024 E610067
G2411190Certificate of AnalysisMar 27, 2024 E610067
G2411191Certificate of AnalysisMar 27, 2024 E610067
G2411192Certificate of AnalysisMar 27, 2024 E610067
G2411193Certificate of AnalysisMar 27, 2024 E610067

Related Documents

Alternative Products

References

1. Genovese MC, Hsia E, Belkowski SM, Chien C, Masterson T, Thurmond RL, Manthey CL, Yan XD, Ge T, Franks C et al..  (2015)  Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy..  J Rheumatol,  42  (10): (1752-60).  [PMID:26233509]

Solution Calculators